Tradestie Institutional Equity Comparison Engine
UNOV vs REGN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
REGN Overall Edge
REGN Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, UNOV trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus REGN at 15.3x Forward P/E and 30.4% operating margin (+36.3% YoY). In options structure, UNOV sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against REGN sits in BREAKOUT (6th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
REGN
UNOV N/M vs REGN 15.3x Fwd P/E
Growth & Margin Winner
REGN
Op Margin N/A vs 30.4% ยท YoY N/A vs +36.3%
Momentum & Technical Winner
REGN
1Y +9.5% vs +37.0% ยท 52W Pos 84% vs 90%
Options & Structure Winner
REGN
UNCLASSIFIED (N/A IV) vs BREAKOUT (6th %ile IV)
UNOV
Cboe BZX
Innovator U.S. Equity Ultra Buffer ETF - November
Pharmaceutical Preparations
$41.13
-0.95% 1D
Market Cap
N/A
1M Return
-0.97%
1Y Return
+9.53%
Forward P/E
N/M
Unified AI Score
58.7 / 100
HOLD
Tech 48.0
Fund 60.0
Flow 50.0
Mom 50.0
REGN
NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$952.40
-0.32% 1D
Market Cap
$98.8B
1M Return
+20.44%
1Y Return
+37.04%
Forward P/E
15.3x
Unified AI Score
38.6 / 100
SELL
Tech 23.0
Fund 43.0
Flow 67.0
Mom 41.1
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
UNOV +9.53%
REGN +37.04%
Spread: +27.51 pp (REGN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
UNOV TTM Op. Margin: N/A
REGN TTM Op. Margin: 30.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UNOV vs REGN. Trailing 12-month operating profitability (UNOV N/A vs REGN 30.4%) and valuation multiples (UNOV N/M vs REGN 15.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | UNOV | REGN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $98.8B | Larger Scale | REGN |
| Trailing P/E Ratio Valuation | N/M | 21.1x | Lower Multiple | REGN |
| Forward P/E Ratio Valuation | N/M | 15.3x | Lower Multiple | REGN |
| Revenue Growth (YoY) Growth | N/A | +36.3% | Higher Growth | REGN |
| Operating Margin (TTM) Profitability | N/A | 30.4% | Higher Margin | REGN |
| Net Profit Margin Profitability | N/A | 28.5% | Higher Margin | REGN |
| Return on Equity (ROE) Capital Efficiency | N/A | 14.9% | Higher ROE | REGN |
| 52-Week Range Position Momentum | 84% ($37โ$42) | 90% ($592โ$992) | Stronger Trend | REGN |
| Beta / 30D Volatility Risk Regime | 0.46ฮฒ ยท 11% Vol | 0.33ฮฒ ยท 55% Vol | Lower Realized Risk | UNOV |
| Unified Institutional Score Composite Signal | 58.7 / 100 (HOLD) | 38.6 / 100 (SELL) | Higher Composite | UNOV |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full UNOV vs REGN Buy Guide
UNOV
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
REGN
BREAKOUT
52d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither UNOV nor REGN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.